Treatment of Respiratory Tract Illness with Bifidobacterium Lactis BL-04

• US 20140112897A1
• Filed: 06/08/2012
• Published: 04/24/2014
• Est. Priority Date: 06/10/2011
• Status: Abandoned Application

• Current Assignee: DuPont Nutrition Biosciences ApS (International Flavors & Fragrances Incorporated)
• Original Assignee: DuPont Nutrition Biosciences ApS (International Flavors & Fragrances Incorporated)
• Inventors: Pyne, David, West, Nicholas, Cripps, Allan, Lahtinen, Sampo
• Application Number:
  US14/124,959
• Publication Number:
  US 20140112897A1
• Time in Patent Office: Days
• US Class Current: 424/93.45
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 11/04 for throat disorders
• CPC Class Codes: A61P 11/14 Antitussive agents
• CPC Class Codes: A61P 27/16 Otologicals
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to a method of treating or prophlaxis of a respiratory tract illness in a subject comprising administering to said subject a composition comprising Bifidobacterium lactis BL04 and/or fermentation product of Bifidobacterium lactis BL04 and/or a cell lysate of Bifidobacterium lactis BL04.

Claims

1. A method of treating or prophlaxis of a respiratory tract illness in a subject comprising administering to said subject a composition comprising Bifidobacterium lactis BL04 and/or fermentation product of Bifidobacterium lactis BL04 and/or a cell lysate of Bifidobacterium lactis BL04.

2. The method according to claim 1, wherein the respiratory tract illness is an upper respiratory tract illness.

3. The method according to claim 1, wherein the respiratory tract illness is a lower respiratory tract illness.

4. The method according to claim 1, wherein the respiratory tract illness is selected from one or more of the group consisting of:

tonsillitis, otitis media;

rhinitis;

rhinosinusitis, sinusitis;

nasopharyngitis, rhinopharyngitis, the common cold;

pharyngitis;

epiglottitis;

supraglottitis;

laryngitis;

laryngotracheitis;

tracheitis;

throat soreness, sneezing, blocked nose, runny nose and a cough.

5. The method according to claim 1 wherein the respiratory tract illness is selected from one or more of the group consisting of:

bronchitis, acute bronchitis, pneumonia and a lung abscess;

coughing with chest congestion and coughing with wheezing.

6. The method according to claim 1, wherein granulocyte phagocytic activity and/or monocyte phagocytic activity in the subject is increased.

7. The method according to claim 2, wherein granulocyte phagocytic activity and/or monocyte phagocytic activity in the subject is increased.

8. The method according to claim 3, wherein granulocyte phagocytic activity and/or monocyte phagocytic activity in the subject is increased.

9. The method according to claim 4, wherein granulocyte phagocytic activity and/or monocyte phagocytic activity in the subject is increased.

10. The method according to claim 5, wherein granulocyte phagocytic activity and/or monocyte phagocytic activity in the subject is increased.

12. The method according to claim 1, wherein the method is prophylactic.

13. The method according to claim 2, wherein the method is prophylactic.

14. The method according to claim 3, wherein the method is prophylactic.

15. The method according to claim 4, wherein the method is prophylactic.

16. The method according to claim 5, wherein the method is prophylactic.

17. The method according to claim 1, wherein the composition comprising Bifidobacterium lactis BL04 is formulated at a dose of 10⁸ to 10¹² CFU of Bifidobacterium lactis BL04/per day.

18. The method according to claim 1, wherein the composition comprising Bifidobacterium lactis BL04 is formulated at a dose of 10⁸ to 10¹² CFU of Bifidobacterium lactis BL04/per day.

19. The method according to claim 2, wherein the composition comprising Bifidobacterium lactis BL04 is formulated at a dose of 10⁸ to 10¹² CFU of Bifidobacterium lactis BL04/per day.

20. The method according to claim 3, wherein the composition comprising Bifidobacterium lactis BL04 is formulated at a dose of 10⁸ to 10¹² CFU of Bifidobacterium lactis BL04/per day.

21. The method according to claim 4, wherein the composition comprising Bifidobacterium lactis BL04 is formulated at a dose of 10⁸ to 10¹² CFU of Bifidobacterium lactis BL04/per day.

22. The method according to claim 5, wherein the composition comprising Bifidobacterium lactis BL04 is formulated at a dose of 10⁸ to 10¹² CFU of Bifidobacterium lactis BL04/per day.

23. The method according to claim 1, comprising administering at least one further probiotic microorganism.

24. The method according to claim 2, comprising administering at least one further probiotic microorganism.

25. The method according to claim 3, comprising administering at least one further probiotic microorganism.

26. The method according to claim 4, comprising administering at least one further probiotic microorganism.

27. The method according to claim 5, comprising administering at least one further probiotic microorganism.

28. The method according to claim 23, wherein the at least one further probiotic microorganism is selected from the genera Lactobacillus, Streptococcus, Enterococcus, Bifidobacterium and Saccharomyces.

29. The method according to claim 1, wherein the composition is formulated a medicament, a food product or a dietary supplement.

30. The method according to claim 2, wherein the composition is formulated a medicament, a food product or a dietary supplement.

31. The method according to claim 3, wherein the composition is formulated a medicament, a food product or a dietary supplement.

32. The method according to claim 4, wherein the composition is formulated a medicament, a food product or a dietary supplement.

33. The method according to claim 5, wherein the composition is formulated a medicament, a food product or a dietary supplement.

11.

34. A method for modifying medication intake in a subject comprising administering an effective amount of a composition comprising Bifidobacterium lactis BL-04 and/or a fermentation product of Bifidobacterium lactis BL-04 and/or a cell lysate of Bifidobacterium lactis BL-04 to a subject.

35. The method of claim 34 wherein the medication is cold or flu medication.

36.